Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 294

1.

Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload.

Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E; Multi-Center Study of Iron Overload Research Group.

Am J Hematol. 2007 Apr;82(4):255-65.

2.

Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease.

Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, Kalinyak KA, Hudes M, Bhatia S, Vichinsky EP; Multi-Centre Study of Iron Overload Research Group.

Br J Haematol. 2006 Nov;135(4):574-82. Epub 2006 Oct 10.

PMID:
17054676
3.
4.
5.

Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.

Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, Hilliard L, Kutlar A, McClain KL, Olivieri NF, Porter JB, Vichinsky EP; Multi-Center Iron Overload Research Group.

Transfusion. 2008 Sep;48(9):1971-80. doi: 10.1111/j.1537-2995.2008.01775.x. Epub 2008 May 29.

6.

Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.

Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.

Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x.

PMID:
19732137
7.

Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia.

Fung EB, Harmatz PR, Milet M, Coates TD, Thompson AA, Ranalli M, Mignaca R, Scher C, Giardina P, Robertson S, Neumayr L, Vichinsky EP; Multi-Center Iron Overload Study Group.

Bone. 2008 Jul;43(1):162-8. doi: 10.1016/j.bone.2008.03.003. Epub 2008 Mar 15.

8.

Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.

Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E.

Blood. 2000 Jul 1;96(1):76-9.

9.

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.

Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.

Am J Hematol. 2008 Apr;83(4):263-70.

10.

Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease.

Jeng MR, Adams-Graves P, Howard TA, Whorton MR, Li CS, Ware RE.

Am J Hematol. 2003 Dec;74(4):243-8.

11.

Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.

Brown K, Subramony C, May W, Megason G, Liu H, Bishop P, Walker T, Nowicki MJ.

J Pediatr Hematol Oncol. 2009 May;31(5):309-12. doi: 10.1097/MPH.0b013e3181a1c143.

PMID:
19415007
12.

Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients.

Hilliard LM, Williams BF, Lounsbury AE, Howard TH.

Am J Hematol. 1998 Sep;59(1):28-35.

13.

Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.

Inati A, Musallam KM, Wood JC, Sheikh-Taha M, Daou L, Taher AT.

Eur J Haematol. 2009 Dec 1;83(6):565-71. doi: 10.1111/j.1600-0609.2009.01345.x. Epub 2009 Sep 8.

PMID:
19737308
14.

Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases.

Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, Khakoo Y, Kinney TR.

Blood. 1995 Nov 15;86(10):3676-84.

15.

[Iron overload in sickle cell anemia : a study of 94 patients].

Hafsia R, Belakhal F, Ben Salah N, Gouider E, Elborgi W.

Tunis Med. 2011 Jun;89(6):548-52. French.

16.

Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia.

Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, Williams R, Louie L, Lee PD, Harmatz P.

Am J Hematol. 2005 Sep;80(1):70-4.

17.

Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease.

Kim HC, Dugan NP, Silber JH, Martin MB, Schwartz E, Ohene-Frempong K, Cohen AR.

Blood. 1994 Feb 15;83(4):1136-42.

18.

Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.

Kim YR, Kim JS, Cheong JW, Song JW, Min YH.

Acta Haematol. 2008;120(3):182-9. doi: 10.1159/000187646. Epub 2009 Jan 5.

PMID:
19129689
19.

Progression of iron overload in sickle cell disease.

Olivieri NF.

Semin Hematol. 2001 Jan;38(1 Suppl 1):57-62.

PMID:
11206962
20.

Chronically transfused pediatric sickle cell patients are protected from cardiac iron overload.

Kaushik N, Eckrich MJ, Parra D, Yang E.

Pediatr Hematol Oncol. 2012 Apr;29(3):254-60. doi: 10.3109/08880018.2011.630774. Epub 2012 Feb 3.

PMID:
22303979
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk